The Akt pathway in oncology therapy and beyond (Review)
- PMID: 30334567
- PMCID: PMC6203150
- DOI: 10.3892/ijo.2018.4597
The Akt pathway in oncology therapy and beyond (Review)
Abstract
Protein kinase B (Akt), similar to many other protein kinases, is at the crossroads of cell death and survival, playing a pivotal role in multiple interconnected cell signaling mechanisms implicated in cell metabolism, growth and division, apoptosis suppression and angiogenesis. Akt protein kinase displays important metabolic effects, among which are glucose uptake in muscle and fat cells or the suppression of neuronal cell death. Disruptions in the Akt‑regulated pathways are associated with cancer, diabetes, cardiovascular and neurological diseases. The regulation of the Akt signaling pathway renders Akt a valuable therapeutic target. The discovery process of Akt inhibitors using various strategies has led to the identification of inhibitors with great selectivity, low side‑effects and toxicity. The usefulness of Akt emerges beyond cancer therapy and extends to other major diseases, such as diabetes, heart diseases, or neurodegeneration. This review presents key features of Akt structure and functions, and presents the progress of Akt inhibitors in regards to drug development, and their preclinical and clinical activity in regards to therapeutic efficacy and safety for patients.
Figures
Similar articles
-
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3. Clin Genitourin Cancer. 2018. PMID: 29199023 Review.
-
Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.Semin Cancer Biol. 2015 Dec;35:180-90. doi: 10.1016/j.semcancer.2015.07.003. Epub 2015 Jul 17. Semin Cancer Biol. 2015. PMID: 26192967 Review.
-
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Expert Opin Investig Drugs. 2010. PMID: 20569080 Review.
-
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065. Sci Transl Med. 2010. PMID: 20686178
-
PI3K and AKT: Unfaithful Partners in Cancer.Int J Mol Sci. 2015 Sep 3;16(9):21138-52. doi: 10.3390/ijms160921138. Int J Mol Sci. 2015. PMID: 26404259 Free PMC article. Review.
Cited by
-
Time required for commitment to T cell proliferation depends on TCR affinity and cytokine response.EMBO Rep. 2023 Jan 9;24(1):e54969. doi: 10.15252/embr.202254969. Epub 2022 Nov 3. EMBO Rep. 2023. PMID: 36327141 Free PMC article.
-
Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.J Med Chem. 2022 Feb 24;65(4):3644-3666. doi: 10.1021/acs.jmedchem.1c02165. Epub 2022 Feb 4. J Med Chem. 2022. PMID: 35119851 Free PMC article.
-
Oxidative Stress and AKT-Associated Angiogenesis in a Zebrafish Model and Its Potential Application for Withanolides.Cells. 2022 Mar 11;11(6):961. doi: 10.3390/cells11060961. Cells. 2022. PMID: 35326412 Free PMC article. Review.
-
Effect of AKT silence on malignant biological behavior of renal cell carcinoma cells.BMC Urol. 2022 Aug 22;22(1):129. doi: 10.1186/s12894-022-01087-4. BMC Urol. 2022. PMID: 35996134 Free PMC article.
-
SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases.Front Oncol. 2022 May 20;12:879457. doi: 10.3389/fonc.2022.879457. eCollection 2022. Front Oncol. 2022. PMID: 35669422 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources